Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies

CC‐486 (oral azacitidine) is an epigenetic modifier in clinical development for treatment of hematological cancers. This study of extended CC‐486 dosing included patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). After a pharmacok...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Hematol
Main Authors: Savona, Michael R., Kolibaba, Kathryn, Conkling, Paul, Kingsley, Edwin C., Becerra, Carlos, Morris, John C., Rifkin, Robert M., Laille, Eric, Kellerman, Amy, Ukrainskyj, Stacey M., Dong, Qian, Skikne, Barry S.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2018
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6221082/
https://ncbi.nlm.nih.gov/pubmed/30016552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25216
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados